Literature DB >> 27981515

Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.

Vincenzo Marotta1, Concetta Sciammarella2, Mario Capasso3, Alessandro Testori3, Claudia Pivonello4, Maria Grazia Chiofalo5, Rosario Pivonello4, Luciano Pezzullo5, Gerardo Botti6, Annamaria Colao4, Antongiulio Faggiano5.   

Abstract

Entities:  

Keywords:  Complete Linkage Disequilibrium; Differentiate Thyroid Cancer; Differentiate Thyroid Cancer Patient; RECIST Response; Sorafenib

Mesh：

Substances：

Year:  2016        PMID： 27981515     DOI： 10.1007/s12020-016-1200-6

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  32 in total

1.  Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection.

Authors:  Majid Shahbazi; Anthony A Fryer; Vera Pravica; Iain J Brogan; Helen M Ramsay; Ian V Hutchinson; Paul N Harden
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

2.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

3.  Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

Authors:  Michael B Bass; Steven I Sherman; Martin J Schlumberger; Martn J Schlumberger; Michael T Davis; Lisa Kivman; Huan-Mei Khoo; Kimberly H Notari; Matthew Peach; Yong-Jiang Hei; Scott D Patterson
Journal:  J Clin Endocrinol Metab       Date:  2010-08-25       Impact factor: 5.958

Review 4.  Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.

Authors:  Stefania Bulotta; Marilena Celano; Giuseppe Costante; Diego Russo
Journal:  Endocrine       Date:  2015-12-21       Impact factor: 3.633

5.  Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival.

Authors:  Felicity Lose; Christina M Nagle; Tracy O'Mara; Jyotsna Batra; Kelly L Bolton; Honglin Song; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Mary-Anne Kedda; Amanda B Spurdle
Journal:  Gynecol Oncol       Date:  2010-09-15       Impact factor: 5.482

6.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

7.  Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.

Authors:  Yoshihisa Kawai; Shigeru Sakano; Yoshihito Korenaga; Satoshi Eguchi; Katsusuke Naito
Journal:  Eur Urol       Date:  2007-01-30       Impact factor: 20.096

8.  The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.

Authors:  Joanna Klubo-Gwiezdzinska; Roman Junik; Ewa Kopczynska; Olga Juraniec; Hanna Kardymowicz
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

9.  Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.

Authors:  G Lurje; W Zhang; A M Schultheis; D Yang; S Groshen; A E Hendifar; H Husain; M A Gordon; F Nagashima; H M Chang; H-J Lenz
Journal:  Ann Oncol       Date:  2008-06-11       Impact factor: 32.976

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  5 in total

1.  Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer.

Authors:  Nicole M Iñiguez-Ariza; Keith C Bible
Journal:  Endocrine       Date:  2017-06-22       Impact factor: 3.633

2.  Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter.

Authors:  A Molinaro; P Orlandi; F Niccolai; P Agretti; G De Marco; E Ferrarini; C Di Cosmo; P Vitti; P Piaggi; T Di Desidero; G Bocci; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2019-08-02       Impact factor: 4.256

Review 3.  Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.

Authors:  Anne Christine Kaae; Michael C Kreissl; Marcus Krüger; Manfred Infanger; Daniela Grimm; Markus Wehland
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

4.  A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.

Authors:  Nigel Fleeman; Rachel Houten; Marty Chaplin; Sophie Beale; Angela Boland; Yenal Dundar; Janette Greenhalgh; Rui Duarte; Aditya Shenoy
Journal:  BMC Cancer       Date:  2019-12-12       Impact factor: 4.430

5.  FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.

Authors:  Pia Adam; Stefan Kircher; Iuliu Sbiera; Viktoria Florentine Koehler; Elke Berg; Thomas Knösel; Benjamin Sandner; Wiebke Kristin Fenske; Hendrik Bläker; Constantin Smaxwil; Andreas Zielke; Bence Sipos; Stephanie Allelein; Matthias Schott; Christine Dierks; Christine Spitzweg; Martin Fassnacht; Matthias Kroiss
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-12       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.